Indeed, the interaction between immune system and tumor as well as prognostic effects of TILs in HER2-positive BC is impacted by various combined therapy modalities, including anti-HER2 therapy, chemotherapy, and hormonal therapy (108). This evidence concerns the gene ERBB2 and neoplasm.